Sqi Diagnostics Inc (SQIDF) 0.2398 $SQIDF
SQI Diagnostics Reports Second Quarter 2016 Results
CNW Group - Fri May 13, 7:30AM CDT
SQI Diagnostics Inc. ("SQI" or the "Company"
(TSX-V: SQD; OTCQX: SQIDF), today reported its financial and operational results for the three and six months ended March 31, 2016.
SQD.VN: 0.320 (unch)
SQI Diagnostics to Announce Second Quarter 2016 Results
PR Newswire - Fri Apr 29, 7:48AM CDT
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company" (TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results for the three and six months ended March 31, 2016 at 8:30am EST Friday, May 13, 2016. President and CEO, Andrew Morris, along with Company management, will host a conference call on Friday, May 13, 2016 at 10:00 a.m. ET to review financial results and discuss business developments for the period.
SQD.VN: 0.320 (unch)
Allergan to Highlight SQI Diagnostics' Technology at 10th WRIB Conference
PR Newswire - Mon Apr 18, 9:56AM CDT
SQI Diagnostics Inc. . ("SQI Diagnostics" "SQI" or the "Company" (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics today announced that its immunogenicity testing technology is being presented by Allergan at the 10th Workshop on Recent Issues in Bioanalysis in Orlando, Florida ("10th WRIB", on April 19, 2016.
AGN: 246.96 (-0.16), SQD.VN: 0.320 (unch)
SQI Sells Sqidlite(TM)-dh System to a Major Diagnostics Customer
CNW Group - Tue Mar 29, 1:59PM CDT
Major Milestone in Commercialization
SQD.VN: 0.320 (unch)
SQI Sells Sqidlite™-dh System to a Major Diagnostics Customer
PR Newswire - Tue Mar 29, 1:59PM CDT
Major Milestone in Commercialization
SQD.VN: 0.320 (unch)
SQI Diagnostics Announces Stock Option Grant
CNW Group - Wed Mar 16, 4:00PM CDT
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company" (TSX-V: SQD; OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective March 14, 2016, it has granted 2,054,000 stock options as part of a Company-wide long-term incentive plan. The goal of the grant is to align the interest of all employees with those of shareholders. 1,638,000 options have been granted to certain officers and directors. Independent directors did not receive options in this grant.
SQD.VN: 0.320 (unch)
SQI Diagnostics to Extend Warrant Expiry
CNW Group - Fri Mar 11, 11:07AM CST
SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI", today announced that it intends to extend the expiry of 8,400,000 outstanding common share purchase warrants ("the Warrants" of the Company, which were issued in connection with the Company's April 2014 public offering of units of the Company. The extension of the warrants was approved by members of the Board of Directors who are independent of this series of warrants. The extension is subject to approval from the TSX Venture Exchange.
SQD.VN: 0.320 (unch)
SQI Diagnostics to Announce First Quarter 2016 Results
PR Newswire - Thu Feb 04, 8:00AM CST
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company" (TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results for the three months ended December 31, 2015 at 8:30am ET Thursday, February 11, 2016. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday February 11, 2016 at 10:00 a.m. ET to review financial results and discuss business developments for the period.
SQD.VN: 0.320 (unch)
SQI Diagnostics Reports Fourth Quarter and Fiscal 2015 Results
PR Newswire - Wed Dec 16, 4:00PM CST
Multiple Customer Agreements Position SQI for Realization of Commercial Revenues in 2016
SQD.VN: 0.320 (unch)
SQI Diagnostics to Announce Fourth Quarter and Fiscal 2015 Results
CNW Group - Thu Dec 10, 3:08PM CST
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company" (TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results the fourth quarter and fiscal year ended September 30, 2015, after market close on Wednesday, December 16, 2015. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday December 17, 2015 at 10:00 a.m. ET to review financial results and discuss business developments for the period.
SQD.VN: 0.320 (unch)
SQI Diagnostics Formalizes Multiple Contracts With Global Pharmaceutical Firm
PR Newswire - Thu Oct 22, 3:45PM CDT
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company" (TSX-V: SQD; OTCQX: SQIDF), today announced a product development agreement with a global pharmaceutical company that formalizes the terms of multiple drug initiatives over the next three years.
SQD.VN: 0.320 (unch)
SQI Diagnostics Reports Second Quarter 2016 Results
CNW Group - Fri May 13, 7:30AM CDT
SQI Diagnostics Inc. ("SQI" or the "Company"
(TSX-V: SQD; OTCQX: SQIDF), today reported its financial and operational results for the three and six months ended March 31, 2016. SQD.VN: 0.320 (unch)
SQI Diagnostics to Announce Second Quarter 2016 Results
PR Newswire - Fri Apr 29, 7:48AM CDT
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company"
(TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results for the three and six months ended March 31, 2016 at 8:30am EST Friday, May 13, 2016. President and CEO, Andrew Morris, along with Company management, will host a conference call on Friday, May 13, 2016 at 10:00 a.m. ET to review financial results and discuss business developments for the period. SQD.VN: 0.320 (unch)
Allergan to Highlight SQI Diagnostics' Technology at 10th WRIB Conference
PR Newswire - Mon Apr 18, 9:56AM CDT
SQI Diagnostics Inc. . ("SQI Diagnostics" "SQI" or the "Company"
(TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics today announced that its immunogenicity testing technology is being presented by Allergan at the 10th Workshop on Recent Issues in Bioanalysis in Orlando, Florida ("10th WRIB", on April 19, 2016. AGN: 246.96 (-0.16), SQD.VN: 0.320 (unch)
SQI Sells Sqidlite(TM)-dh System to a Major Diagnostics Customer
CNW Group - Tue Mar 29, 1:59PM CDT
Major Milestone in Commercialization
SQD.VN: 0.320 (unch)
SQI Sells Sqidlite™-dh System to a Major Diagnostics Customer
PR Newswire - Tue Mar 29, 1:59PM CDT
Major Milestone in Commercialization
SQD.VN: 0.320 (unch)
SQI Diagnostics Announces Stock Option Grant
CNW Group - Wed Mar 16, 4:00PM CDT
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company"
(TSX-V: SQD; OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective March 14, 2016, it has granted 2,054,000 stock options as part of a Company-wide long-term incentive plan. The goal of the grant is to align the interest of all employees with those of shareholders. 1,638,000 options have been granted to certain officers and directors. Independent directors did not receive options in this grant. SQD.VN: 0.320 (unch)
SQI Diagnostics to Extend Warrant Expiry
CNW Group - Fri Mar 11, 11:07AM CST
SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI"
, today announced that it intends to extend the expiry of 8,400,000 outstanding common share purchase warrants ("the Warrants" of the Company, which were issued in connection with the Company's April 2014 public offering of units of the Company. The extension of the warrants was approved by members of the Board of Directors who are independent of this series of warrants. The extension is subject to approval from the TSX Venture Exchange. SQD.VN: 0.320 (unch)
SQI Diagnostics to Announce First Quarter 2016 Results
PR Newswire - Thu Feb 04, 8:00AM CST
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company"
(TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results for the three months ended December 31, 2015 at 8:30am ET Thursday, February 11, 2016. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday February 11, 2016 at 10:00 a.m. ET to review financial results and discuss business developments for the period. SQD.VN: 0.320 (unch)
SQI Diagnostics Reports Fourth Quarter and Fiscal 2015 Results
PR Newswire - Wed Dec 16, 4:00PM CST
Multiple Customer Agreements Position SQI for Realization of Commercial Revenues in 2016
SQD.VN: 0.320 (unch)
SQI Diagnostics to Announce Fourth Quarter and Fiscal 2015 Results
CNW Group - Thu Dec 10, 3:08PM CST
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company"
(TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results the fourth quarter and fiscal year ended September 30, 2015, after market close on Wednesday, December 16, 2015. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday December 17, 2015 at 10:00 a.m. ET to review financial results and discuss business developments for the period. SQD.VN: 0.320 (unch)
SQI Diagnostics Formalizes Multiple Contracts With Global Pharmaceutical Firm
PR Newswire - Thu Oct 22, 3:45PM CDT
SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company"
(TSX-V: SQD; OTCQX: SQIDF), today announced a product development agreement with a global pharmaceutical company that formalizes the terms of multiple drug initiatives over the next three years. SQD.VN: 0.320 (unch)
